Not to exceed 250 mL once daily for 60 min. Duration: Acute exacerbation in chronic bronchitis 5 days. Community-acquired pneumonia 7-14 days (sequential oral following IV administration). Uncomplicated skin & soft tissue infection 7 days. Complicated skin & soft tissue infection 7-21 days (sequential oral following IV administration). Complicated intraabdominal infection 5-14 days (sequential oral following IV administration).
View Pol-Moxi overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to moxifloxacin or other quinolones. Patients w/ history of tendon disease/disorder related to quinolone treatment; congenital or documented acquired QT prolongation; electrolyte disturbances particularly uncorrected hypokalaemia; clinically relevant bradycardia; clinically relevant heart failure w/ reduced left-ventricular ejection fraction; previous history of symptomatic arrhythmias. Not to be used concurrently w/ other drugs prolonging the QT interval. Hepatic impairment (Child-Pugh C) & patients w/ transaminases increase >5 fold ULN. Pregnancy & lactation. Childn <18 yr.
Hypersensitivity & allergic reactions. Discontinue use if signs or symptoms that may be associated w/ cardiac arrhythmia w/ or w/o ECG findings occur. Patients w/ any condition predisposing to cardiac arrhythmias (eg, acute myocardial ischaemia); CNS disorders or in presence of other risk factors which may predispose to seizures or lower seizure threshold. Bullous skin reactions eg, SJS or TEN. Sensory or sensorimotor polyneuropathy resulting in paraesthesia, hypoaesthesia, dysaesthesia or weakness. Psychiatric reactions may occur even after 1st administration. Concomitant use w/ medications reducing K levels. Fulminant hepatitis potentially leading to liver failure (including fatal cases). Not to be used during pregnancy.
Superinfections due to resistant bacteria or fungi eg, oral & vag candidiasis; headache, dizziness; QT prolongation in patients w/ hypokalaemia; nausea, vomiting, GI & abdominal pains, diarrhoea; increase in transaminases; inj & infusion site reactions.
Sign Out
